Cargando…

2503. Differences Between Experts and Community Clinicians in Selecting HIV Switch Regimens for Patients With Viral Suppression

BACKGROUND: Patients and clinicians may consider switching suppressive HIV regimens for a variety of reasons, including simplification, improved safety and tolerability, drug interactions, or cost. Because switching treatment is a common clinical dilemma in current HIV care, we developed an online t...

Descripción completa

Detalles Bibliográficos
Autores principales: Blanchette, Jennifer, Schulz, Jenny, King, Edward, Wood, Brian, Eron, Joseph J, Sax, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810329/
http://dx.doi.org/10.1093/ofid/ofz360.2181
_version_ 1783462224466018304
author Blanchette, Jennifer
Schulz, Jenny
King, Edward
Wood, Brian
Eron, Joseph J
Sax, Paul
author_facet Blanchette, Jennifer
Schulz, Jenny
King, Edward
Wood, Brian
Eron, Joseph J
Sax, Paul
author_sort Blanchette, Jennifer
collection PubMed
description BACKGROUND: Patients and clinicians may consider switching suppressive HIV regimens for a variety of reasons, including simplification, improved safety and tolerability, drug interactions, or cost. Because switching treatment is a common clinical dilemma in current HIV care, we developed an online treatment decision support tool to assist providers on selecting a new regimen in a variety of patient scenarios. METHODS: In March 2018, 5 HIV experts provided treatment recommendations for more than 1300 unique HIV switch case scenarios based on a simplified set of variables: CVD, HLA-B*5701, HBV, drug resistance, current ART, and component requiring a switch. We then developed a decision support tool that enabled clinicians to specify a patient scenario using these variables and to select their currently intended approach. The experts’ recommendations for that specific case were then shown, and clinicians were asked if the recommendations changed their planned treatment. RESULTS: In the 5 months following release of the tool, healthcare providers (HCPs) entered 932 patient case scenarios. A comparison of HCPs treatment plans vs expert selections in select patient case scenarios is shown in Tables 1 and 2. The data demonstrated several key areas of discordance, including the more frequent selection of the following options by HCPs vs. experts across a wide range of case scenarios: (a) Boosted regimens: 18% to 31% vs. 0% to 4% of cases; (b) TDF-containing regimens: 7% to 25% vs. 0% of cases; and (c) PI-based regimens: 9% to 23% vs. 0% to 4% of cases. In a subset of 88 patient case scenarios where HCPs’ intended treatment differed from experts and HCPs also self-identified the impact of the tool, 48% indicated that their treatment plan would change/agreed with experts after using the tool. CONCLUSION: This online HIV switch decision support tool shows substantial differences between experts’ and HCPs’ treatment choices for switching therapy in multiple case scenarios. Moreover, consensus expert selections in this online tool resulted in a change to the intended treatment plan for approximately one half of users, suggesting use of the tool can help optimize selection of a new ART regimen for patients switching in the setting of virologic suppression. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810329
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68103292019-10-28 2503. Differences Between Experts and Community Clinicians in Selecting HIV Switch Regimens for Patients With Viral Suppression Blanchette, Jennifer Schulz, Jenny King, Edward Wood, Brian Eron, Joseph J Sax, Paul Open Forum Infect Dis Abstracts BACKGROUND: Patients and clinicians may consider switching suppressive HIV regimens for a variety of reasons, including simplification, improved safety and tolerability, drug interactions, or cost. Because switching treatment is a common clinical dilemma in current HIV care, we developed an online treatment decision support tool to assist providers on selecting a new regimen in a variety of patient scenarios. METHODS: In March 2018, 5 HIV experts provided treatment recommendations for more than 1300 unique HIV switch case scenarios based on a simplified set of variables: CVD, HLA-B*5701, HBV, drug resistance, current ART, and component requiring a switch. We then developed a decision support tool that enabled clinicians to specify a patient scenario using these variables and to select their currently intended approach. The experts’ recommendations for that specific case were then shown, and clinicians were asked if the recommendations changed their planned treatment. RESULTS: In the 5 months following release of the tool, healthcare providers (HCPs) entered 932 patient case scenarios. A comparison of HCPs treatment plans vs expert selections in select patient case scenarios is shown in Tables 1 and 2. The data demonstrated several key areas of discordance, including the more frequent selection of the following options by HCPs vs. experts across a wide range of case scenarios: (a) Boosted regimens: 18% to 31% vs. 0% to 4% of cases; (b) TDF-containing regimens: 7% to 25% vs. 0% of cases; and (c) PI-based regimens: 9% to 23% vs. 0% to 4% of cases. In a subset of 88 patient case scenarios where HCPs’ intended treatment differed from experts and HCPs also self-identified the impact of the tool, 48% indicated that their treatment plan would change/agreed with experts after using the tool. CONCLUSION: This online HIV switch decision support tool shows substantial differences between experts’ and HCPs’ treatment choices for switching therapy in multiple case scenarios. Moreover, consensus expert selections in this online tool resulted in a change to the intended treatment plan for approximately one half of users, suggesting use of the tool can help optimize selection of a new ART regimen for patients switching in the setting of virologic suppression. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810329/ http://dx.doi.org/10.1093/ofid/ofz360.2181 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Blanchette, Jennifer
Schulz, Jenny
King, Edward
Wood, Brian
Eron, Joseph J
Sax, Paul
2503. Differences Between Experts and Community Clinicians in Selecting HIV Switch Regimens for Patients With Viral Suppression
title 2503. Differences Between Experts and Community Clinicians in Selecting HIV Switch Regimens for Patients With Viral Suppression
title_full 2503. Differences Between Experts and Community Clinicians in Selecting HIV Switch Regimens for Patients With Viral Suppression
title_fullStr 2503. Differences Between Experts and Community Clinicians in Selecting HIV Switch Regimens for Patients With Viral Suppression
title_full_unstemmed 2503. Differences Between Experts and Community Clinicians in Selecting HIV Switch Regimens for Patients With Viral Suppression
title_short 2503. Differences Between Experts and Community Clinicians in Selecting HIV Switch Regimens for Patients With Viral Suppression
title_sort 2503. differences between experts and community clinicians in selecting hiv switch regimens for patients with viral suppression
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810329/
http://dx.doi.org/10.1093/ofid/ofz360.2181
work_keys_str_mv AT blanchettejennifer 2503differencesbetweenexpertsandcommunitycliniciansinselectinghivswitchregimensforpatientswithviralsuppression
AT schulzjenny 2503differencesbetweenexpertsandcommunitycliniciansinselectinghivswitchregimensforpatientswithviralsuppression
AT kingedward 2503differencesbetweenexpertsandcommunitycliniciansinselectinghivswitchregimensforpatientswithviralsuppression
AT woodbrian 2503differencesbetweenexpertsandcommunitycliniciansinselectinghivswitchregimensforpatientswithviralsuppression
AT eronjosephj 2503differencesbetweenexpertsandcommunitycliniciansinselectinghivswitchregimensforpatientswithviralsuppression
AT saxpaul 2503differencesbetweenexpertsandcommunitycliniciansinselectinghivswitchregimensforpatientswithviralsuppression